NAGE Niagen Bioscience, Inc.
Niagen Bioscience, Inc. (NAGE) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is $0.00 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.9% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.